Neurological Biomarkers for Drug Development
We have deep neurodegenerative biomarker experience to power your decisions.
Biomarkers are at the heart of today’s drug development and the pursuit of medicines for neurodegenerative diseases.
Labcorp has analyzed nearly 30,000 neurodegenerative clinical trial and study samples on the Quanterix™ platform and has expertise in running the following:
| Biomarker | Associated Diseases | ||||||||||
| NfL | Neurodegeneration: MS, ALS, AD, PD, FTD (frontotemperal dementia), HAND (HIV associated neurocognitive disorder), COVID-19 associated neurological disorders, concussion/mTBI | ||||||||||
| GFAP | Neurodegeneration: MS, AD, NMOSD (neuromyelitis optica spectrum disorder), COVID-19 associated neurological disorders, concussion/mTBI | ||||||||||
| p-tau181 | AD | ||||||||||
| Total tau | Tauopathies: AD, FTD with Parkinsons (PD), PSP (progressive supranuclear palsy), HAND, concussion/mTBI | ||||||||||
| Neuro 3-plex: Amyloid beta (1-42), Amyloid beta (1-40), total tau | AD, HAND | ||||||||||
| Neuro 4-plex E: Amyloid beta (1-42), Amyloid beta (1-40), NF-L and GFAP | AD | ||||||||||
| Neuro 4-plex A: NF-L, GFAP, Total Tau, UCH-L1 | Concussion/mTBI | ||||||||||
| a-synuclein | PD, AD | ||||||||||
| Amyloid beta (1-42) | AD | ||||||||||
| p-tau231 | AD | ||||||||||
| Cytokine 3-plex: IL-6, TNFa, IL-10 | AD (inflammation) | ||||||||||